US Stock MarketDetailed Quotes
COGT Cogent Biosciences
- 7.860
- +0.100+1.29%
Close Dec 24 13:00 ET
- 7.860
- 0.0000.00%
Post 13:01 ET
868.23MMarket Cap-3.17P/E (TTM)
7.880High7.620Low537.25KVolume7.750Open7.760Pre Close4.18MTurnover0.84%Turnover RatioLossP/E (Static)110.46MShares12.61052wk High4.26P/B504.65MFloat Cap4.28052wk Low--Dividend TTM64.21MShs Float174.200Historical High--Div YieldTTM3.35%Amplitude1.904Historical Low7.781Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Cogent Biosciences Stock Forum
based on a quick AI research:
AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.
Based on the recent clinical data, here are Cogent Biosciences' potential advantages:
1. Efficacy Advantages:
◦ 83% ORR (mIWG criteria)
◦ 100% ORR (PPR criteria)
– Higher response rate at optimal dose (100mg BID):
– Quick response time (2.2 months)
– Potentially better than existing treatments
1. Potential Market Differentiati...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 pat...
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID
88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID
Median time to response 2.2 months with median duration of response and median PFS not yet reach...
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
GlobeNewswire· 30 mins ago
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
No comment yet